Patient
SITE014-0032
enrolled Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE014 (NLD) (Dr. Moreau)
consented 2025-10-05
Adverse events
4
Serious AEs
1
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 4
Grade 4 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-11-22 (study day 227); relationship: not assessed; serious criteria: life-threatening
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-11-08 (study day 213); relationship: not assessed
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-10-30 (study day 204); relationship: NOT RELATED
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-07-02 (study day 84); relationship: RELATED
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.